APA (7th ed.) Citation

Shang, X., Zhao, G., Liang, F., Zhang, C., Zhang, W., Liu, L., . . . Jiang, H. (2022). Safety and effectiveness of pembrolizumab combined with paclitaxel and cisplatin as neoadjuvant therapy followed by surgery for locally advanced resectable (stage III) esophageal squamous cell carcinoma: A study protocol for a prospective, single-arm, single-center, open-label, phase-II trial (Keystone-001). Annals of translational medicine, 10(4), 229. https://doi.org/10.21037/atm-22-513

Chicago Style (17th ed.) Citation

Shang, Xiaobin, et al. "Safety and Effectiveness of Pembrolizumab Combined with Paclitaxel and Cisplatin as Neoadjuvant Therapy Followed by Surgery for Locally Advanced Resectable (stage III) Esophageal Squamous Cell Carcinoma: A Study Protocol for a Prospective, Single-arm, Single-center, Open-label, Phase-II Trial (Keystone-001)." Annals of Translational Medicine 10, no. 4 (2022): 229. https://doi.org/10.21037/atm-22-513.

MLA (9th ed.) Citation

Shang, Xiaobin, et al. "Safety and Effectiveness of Pembrolizumab Combined with Paclitaxel and Cisplatin as Neoadjuvant Therapy Followed by Surgery for Locally Advanced Resectable (stage III) Esophageal Squamous Cell Carcinoma: A Study Protocol for a Prospective, Single-arm, Single-center, Open-label, Phase-II Trial (Keystone-001)." Annals of Translational Medicine, vol. 10, no. 4, 2022, p. 229, https://doi.org/10.21037/atm-22-513.